Skip to main content
Fig. 7 | Arthritis Research & Therapy

Fig. 7

From: The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

Fig. 7

Total sIL-6R serum levels in the CIA study in rhesus monkeys. Curves depict results from individual animals. Acute responders and animals with neutralizing and/or clearing ADAs are indicated in black. Colored lines indicate animals with active drug levels throughout the entire study. Animals with high discomfort scores had to be euthanized during the study period. (a) Total sIL-6R levels after 7.5 mg/kg ALX-0061 treatment. (b) Total sIL-6R levels after 10 mg/kg TCZ treatment. ADA: anti-drug antibodies; CIA: collagen-induced arthritis; sIL-6R: soluble interleukin-6 receptor; TCZ: tocilizumab

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us